A comparative analysis on the efficacy and safety of intaxelspi® and taxolspi® in advanced metastatic breast cancer

Istvan Lang, Gabor Rubovszky, Zsolt Horvath, Erna Ganofszky, Eszter Szabo, Magdolna Dank, Katalin Boer, Erika Hitre

Research output: Article

3 Citations (Scopus)


Background: Among the presently available cytotoxic drugs, paclitaxel, in combination with doxorubicin and carboplatin, come under the highly active therapy for metastatic breast cancer. Between the two brands of paclitaxel (Intaxel, which is marketed by Dabur Oncology and Taxol, the original paclitaxel which is manufactured by BMS) the similarity has not been evaluated in clinical trial settings till date. This prospective, controlled, randomized, multicentre, open-label phase IV study was planned to compare the safety and efficacy of Intaxel with Taxol, when they were used in combination with carboplatin or doxorubicin, as a second line treatment for metastatic breast cancer. Methods: Fourty nine eligible patients were randomized to receive Intaxel or Taxol with either doxorubicin or carboplatin. The patients who had received a prior anthracycline based chemotherapy were randomized to the paclitaxel/carboplatin arm. The patients were evaluated in three phases i.e. at baseline, during the treatment and at follow up for the tumour response, the time period till the disease progression and the toxicity. The time till the disease progression was assessed by the Kaplan-Meier method. The continuous and categorical variables were assessed by using the ANOVA test and Fisher's exact test, respectively. Results: After 3 cycles, an objective response rate of 55.56% (CR = 3, PR = 7) was noted in the Intaxel group and that of 59.09% (CR = 1, PR = 12) was noted in the Taxol group. After 6 cycles, an objective response rate of 50% was noted in both the groups. No significant difference was observed in the response rate of the two groups after 3 cycles (p > 0.05) and at the end of the treatment (p > 0.05). The patients who received Intaxel had a lower incidence of thrombocytopaenia (p = 0.0146) and neurosensory loss (p = 0.008) as compared to those who received Taxol. Conclusion: The results of this study demonstrated that the safety and efficacy of Intaxel and Taxol are equivalent when they are used in combination with other cytotoxic agents as the second line of treatment for metastatic stage IV breast cancer.

Original languageEnglish
Pages (from-to)1120-1124
Number of pages5
JournalJournal of Clinical and Diagnostic Research
Issue number6
Publication statusPublished - jún. 1 2013

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'A comparative analysis on the efficacy and safety of intaxelspi® and taxolspi® in advanced metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this